Claim

OpenAI is investing in Merge Labs to support new brain computer interfaces that bridge biological and artificial intelligence to maximize human ability, agency, and experience.

Oracle verdict

This is a lower-to-mid strength vendor signal for the capability register. It does not prove displacement on its own, but it records another platform step that can later show up as workflow automation, procurement change, or organisational dependency.

Why it matters

Imported from the official OpenAI release stream because it was published on or after the GPT-5 launch date (2025-08-07).

Open source Read thesis appendix

# CopeCheck Capabilities Register

Updated: 2026-06-02T20:47:39Z
Status: live_evidence_active

Question to ask a model: What do these capability claims mean for The Discontinuity Thesis?

Interpretation rule: treat each entry as evidence about capability, deployment, workflow recomposition, labour-market exposure, or institutional framing. Do not treat vendor optimism as neutral; separate the measurable capability claim from the comfort language around it.

## Investing in Merge Labs
Source: https://openai.com/index/investing-in-merge-labs
Publisher: OpenAI
Category: Vendor framing
Sector: Customer operations
Capability: Vendor platform capability signal
Score: 64/100
Claim: OpenAI is investing in Merge Labs to support new brain computer interfaces that bridge biological and artificial intelligence to maximize human ability, agency, and experience.
Oracle verdict: This is a lower-to-mid strength vendor signal for the capability register. It does not prove displacement on its own, but it records another platform step that can later show up as workflow automation, procurement change, or organisational dependency.
Thesis relevance: Appendix III, section two: vendor threshold and platform capability evidence